Periprocedural Myocardial Necrosis
Conditions
Keywords
Percutaneous angioplasty, Myocardial Infarction
Brief summary
An increase in cardiac biomarkers has been shown to occur in 5% to 30% of patients after otherwise successful percutaneous coronary interventions (PCIs)(1) Apart from side-branch occlusion, intimal dissection and coronary spasm, a possible aetiology of myonecrosis after PCI might be distal embolization of atherogenic materials from plaque disruption,(2 )causing obstruction of blood flow at capillary level resulting in micro-infarction.(3,4 )Recent studies have suggested that pretreatment with Atorvastatin may be associated with a reduction in infarct size after elective PCI. (5-7 ).Actually the standard pretreatment in patients undergoing elective coronary-PCI and already treated with aspirin is copidogrel loading dose administration before procedure.(8,9 ) The investigators hypothesized that a high (40mg) loading dose of Rosuvastatin administered within 24h before the procedure may be effective in reducing the rate of periprocedural MI.Therefore, the investigators will conduct a single center,prospective randomized study to assess whether a single,high (40mg) loading (within24h)dose of Rosuvastatin is effective in preventing elevation of biomarkers of MI after elective coronary stent implantation.
Interventions
DRUGROSUVASTATIN
40 mg before procedure
Sponsors
University of Roma La Sapienza
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with stable angina
Exclusion criteria
* Baseline myocardial enzyme rise
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Myocardial enzymes arise | 6-12-24 hours |
Secondary
| Measure | Time frame |
|---|---|
| MACE | 1-6-9 MONTHS |
Countries
Italy
Outcome results
None listed